Additional data suggest that targeting SHP2 may represent an effective strategy for treatment of epidermal growth factor receptor (EGFR) inhibitor resistant non-small cell lung cancer [31]. The gene discussed is PTPN11; the disease is non-small cell lung carcinoma.